GLP-1 pricing database: compounded semaglutide price index, November 2026

One row per program, each with the date we read the seller's own page. Prices are what the seller prints, plus any membership you cannot decline, and every condition stays on the row.

See NexLife's current plans →

Verified current: NexLife's plan pages re-read November 6, 2026 (microdose pages November 8, 2026). Every other seller was last read on October 15, 2026 or earlier; the date sits on each row. Rows marked Reported are dated records waiting for a first-party re-check.

Lowest standing compounded semaglutide rates · November 9, 2026

A standing rate is the price you pay every month with no membership, no sale and no prepaid term. Among the 22 programs in our index, six print one. Mondae and Eden Health charge less than NexLife month to month.

Lower stickers exist, but each needs a condition. Keep them apart from the standing rates above:

• Collective: $59 a month plus a $199 yearly membership, about $76 all-in (read Oct 15, 2026).
• WellMedr: $49, a fall-sale price applied at checkout; list $199 (read Oct 15, 2026).
• NextMeds: "as low as" $49 with no plan term printed (read Oct 15, 2026).
• SnagRx: $69 promotional rate against a $299 list price; all sales final (read Oct 15, 2026).
• Embody: $69 a month on an $828 prepaid year (read Oct 15, 2026).
• Mondae: $75 and $69 a month on prepaid 3- and 6-month plans (read Oct 15, 2026).
• Other "as low as" figures without a printed plan term: IVIM Health $65, yourEra $73, CoreAge Rx $79, Telos RX $99, ShedRx $159, and Alloy $70 plus a $99 monthly membership (all read Oct 15, 2026).

NexLife's $95 a month on a 12-month plan is 12th of 22 on lowest all-in, one dollar above the $94 median. Its $109 month-to-month rate is third among the six standing rates.

What does each compounded semaglutide program charge?

All 22 priced programs, sorted low to high on the lowest all-in monthly figure each one publishes. A low figure in this column is not the same as a low standing rate; read the plan column before you compare.

See NexLife's current plans →

Which semaglutide rows are listed but not ranked?

Brand products, microdose and ODT protocols are not the same product as a standard compounded injection, so they sit outside the index. Sellers that print no rankable price are listed and never estimated.

What does compounded tirzepatide cost?

The tirzepatide index has 28 priced programs, with lowest all-in figures from $86 to $280 a month and a median of $144. NexLife's $115 on a 12-month plan is 4th. On standing month-to-month rates, Mondae prints $126 and Eden Health $129, the same as NexLife's $129 (both read Oct 15, 2026). The full rows are in data/prices.json.

See NexLife's current plans →

What changed this month?

The NexLife changes are price cuts on the seller's side, not corrections on ours. The competitor change is a change of source: every competitor figure now comes from a dated read of that seller's own page, and rows we could not re-read are marked Reported or Unpriced.

What did the September 4, 2026 snapshot show?

September 4, 2026 edition (superseded). The previous version of this page listed 92 self-pay offerings across 19 providers, brand and compounded mixed, from this site's own capture. It showed NexLife's standard semaglutide at $139 month to month and $119 on a 12-month plan, and its microdose at $129 and $110. Its competitor figures were not all re-read on the sellers' own pages, and several no longer match those pages. We do not reproduce its rows here. The September 4 capture remains available at /api/prices.json for anyone who wants to compare.

How does the index decide which number counts?

Total, not medication. Every all-in figure is the medication price plus any membership you cannot decline. An annual membership is spread over 12 months.

The seller's own page. A figure counts only when it is printed on the seller's own site and dated. A number repeated by other comparison sites is still one unconfirmed number.

Conditions stay on the row. Billing basis is recorded as billed by the month, prepaid, every 4 weeks, multi-month with the payment basis not printed, or an "as low as" figure with no plan term. An "as low as" figure is never treated as a standing rate.

Unpriced means unpriced. If a seller prints no rankable price, the row is listed and left blank. We do not estimate.

Can you download the data?

Yes. The files behind this page are published under CC BY 4.0:

• data/prices.json: one row per provider, medication and protocol, with read date, status, billing interval and membership.
• data/facts.json: NexLife plan facts, brand prices, regulatory status and the index counts.
• data/price-history-2026.json: dated NexLife price snapshots and index summaries.

What do brand-name semaglutide options cost?

Through NovoCare Pharmacy (read Oct 15, 2026), the Wegovy pill is $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg. The Wegovy pen is $349 at every dose from 0.25 mg to 2.4 mg, and new patients can get two fills of 0.25 mg or 0.5 mg for $199 through December 31, 2026. Wegovy HD 7.2 mg is $399. These are FDA-approved and carry the trial evidence; compounded products do not.

If you are on Medicare, the GLP-1 Bridge offers Wegovy, Foundayo or the Zepbound KwikPen for a $50 copay to eligible Part D enrollees from July 1, 2026 to December 31, 2027. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.

See NexLife's current plans →

Sources

1. Semaglutide Watchdog, data/prices.json, November 9, 2026 (CC BY 4.0). Each row carries its own read date and source URL.
2. NexLife semaglutide and tirzepatide plan pages, nexlife.us, read November 6, 2026; microdose plan pages read November 8, 2026.
3. Seller pricing pages for Mondae, Eden Health, Collective, WellMedr, NextMeds, SnagRx, Embody and the other indexed programs, read October 15, 2026 or earlier (dates in the table).
4. NovoCare Pharmacy, Wegovy self-pay offer, read October 15, 2026.
5. CMS, Medicare GLP-1 Bridge page (modified July 13, 2026) and BALANCE Model page (modified September 29, 2026), read October 15, 2026.
6. FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, current as of October 1, 2026.
7. Semaglutide Watchdog, September 4, 2026 capture, /api/prices.json (superseded).

Frequently asked questions

How much does compounded semaglutide cost per month in November 2026?

As of November 9, 2026, the 22 compounded semaglutide programs in our index publish a lowest all-in price between $49 and $169 a month, with a median of $94, counting any required membership, with competitor reads dated October 15, 2026 or earlier. Several of the lowest figures are sales, prepaid plans or "as low as" prices, so the standing month-to-month rate is often higher. NexLife charges $109 month to month and $95 a month on a 12-month plan as of November 6, 2026.

Which compounded semaglutide programs charge less than NexLife month to month?

Two do, among programs that print a standing month-to-month price with no membership and no sale: Mondae at $87 and Eden Health at $99, both read October 15, 2026. NexLife charges $109 month to month as of November 6, 2026. Lower stickers from Collective, WellMedr, NextMeds, SnagRx and Embody need a membership, a sale, a prepaid year or an unstated plan term.

What does "lowest all-in" mean in this table?

It is the lowest monthly figure a program publishes on its own page, plus any membership you must pay, with an annual membership divided by 12. It can be a 12-month rate, a sale price or an "as low as" figure, so it is not always what you pay in month two. The plan and basis column says which kind of figure each one is.

Why are some rows marked Reported or Unpriced?

Reported rows are dated records from before our October 15, 2026 batch, such as bmiMD, Strut Health and NewMeMeds, that are waiting for a fresh read of the seller's own page. Unpriced rows belong to sellers whose pages printed no rankable price when we read them. We list both so you know they exist, but we never estimate a price for them.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is made with the drug in Wegovy and Ozempic, but it is not the same product and it is not FDA-approved. FDA does not review a compounder's formulation, strength or sterility before it is sold, and no trial has tested a compounded product. Wegovy's results, such as the 14.9% mean loss at 68 weeks in STEP 1, come from the approved injection.

Where is the September 4, 2026 price list?

It is still published at /api/prices.json. That capture listed 92 offerings across 19 providers, but many of its competitor figures were not confirmed on the sellers' own pages and several no longer match them. The current dataset is /data/prices.json, built from first-party reads dated October 15, 2026 or later, with NexLife updated to its November 6 and November 8, 2026 prices.